All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
2 results for "Cancer" and "Endocrine Cancers" and "Leukemia"
A Phase 1b/2 Study of the Safety, PK, PD and Preliminary Efficacy of the FLT3 Inhibitor Gilteritinib, in Combination with the Selective SYK Inhibitor Lanraplenib (KB-9876), in Patients with FLT3-mutated Relapsed or Refractory AML
To evaluate the safety of LANRA in combination with the FLT3 inhibitor gilteritinib, in patients with R/R FLT3-mutated AML.
A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-cell Malignancies or Acute Myeloid Leukemia after Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and
This project is being done to determine the highest safely tolerated dose of voruciclib in patients that have relapsed and/or refractory B cell type cancers or acute myeloid leukemia.